Century Therapeutics (IPSC) Total Non-Current Liabilities (2024 - 2026)

Century Therapeutics (IPSC) has reported Total Non-Current Liabilities for 3 consecutive years, with $59.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 10.2% year-over-year to $59.9 million; the TTM figure through Mar 2026 stood at $59.9 million (down 10.2% YoY), while the FY2025 annual figure was $61.0 million, down 66.68% from the prior year.
• Total Non-Current Liabilities fell to $59.9 million in Q1 2026 per IPSC's latest filing, from $61.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $185.0 million in Q2 2024 and bottomed at $59.2 million in Q3 2025.
• Historically, Total Non-Current Liabilities has averaged $115.0 million across 3 years, with a median of $66.7 million in 2025.
• Annual changes were most pronounced in 2025 — Total Non-Current Liabilities sank 67.79% — and 2026, when it slipped 10.2%.
• Century Therapeutics' Total Non-Current Liabilities stood at $183.1 million in 2024, then sank by 66.68% to $61.0 million in 2025, then dropped by 1.87% to $59.9 million in 2026.
• Business Quant data shows IPSC's Total Non-Current Liabilities at $59.9 million in Q1 2026, $61.0 million in Q4 2025, and $59.2 million in Q3 2025.